Cantor Fitzgerald Estimates Biohaven FY2025 Earnings

Biohaven Ltd. (NYSE:BHVN) – Cantor Fitzgerald issued their FY2025 earnings estimates for Biohaven in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of ($6.05) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($8.85) per share.

Several other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $59.00 price target on shares of Biohaven in a research note on Tuesday, December 17th. TD Cowen raised their price objective on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. upped their target price on Biohaven from $55.00 to $68.00 and gave the company an “overweight” rating in a research note on Thursday, October 3rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price target (up previously from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. Thirteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $63.00.

Biohaven Price Performance

BHVN opened at $40.56 on Wednesday. The stock’s 50 day simple moving average is $40.63 and its 200 day simple moving average is $42.42. The stock has a market cap of $4.10 billion, a P/E ratio of -4.34 and a beta of 1.29. Biohaven has a 1-year low of $26.80 and a 1-year high of $62.21.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03).

Institutional Trading of Biohaven

Institutional investors have recently modified their holdings of the company. FSC Wealth Advisors LLC raised its position in Biohaven by 3.3% in the fourth quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company’s stock valued at $579,000 after purchasing an additional 500 shares during the period. KBC Group NV boosted its holdings in Biohaven by 50.1% in the 4th quarter. KBC Group NV now owns 3,377 shares of the company’s stock worth $126,000 after acquiring an additional 1,127 shares during the period. Inspire Investing LLC grew its position in Biohaven by 32.9% in the fourth quarter. Inspire Investing LLC now owns 10,895 shares of the company’s stock valued at $407,000 after acquiring an additional 2,698 shares in the last quarter. ARS Investment Partners LLC raised its stake in shares of Biohaven by 1.0% during the fourth quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company’s stock valued at $38,871,000 after purchasing an additional 10,473 shares during the period. Finally, Weybosset Research & Management LLC lifted its position in shares of Biohaven by 23.9% during the fourth quarter. Weybosset Research & Management LLC now owns 13,645 shares of the company’s stock worth $510,000 after purchasing an additional 2,635 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Insiders Place Their Bets

In other news, Director John W. Childs purchased 29,000 shares of the company’s stock in a transaction on Monday, December 30th. The stock was bought at an average cost of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the purchase, the director now directly owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. The trade was a 1.24 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 16.00% of the stock is owned by corporate insiders.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.